Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cartesian Therapeutics (RNAC) Shares Outstanding (Weighted Average): 2016-2025

Historic Shares Outstanding (Weighted Average) for Cartesian Therapeutics (RNAC) over the last 10 years, with Sep 2025 value amounting to $26.0 million.

  • Cartesian Therapeutics' Shares Outstanding (Weighted Average) rose 6.89% to $26.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.0 million, marking a year-over-year increase of 6.89%. This contributed to the annual value of $25.4 million for FY2024, which is 391.25% up from last year.
  • According to the latest figures from Q3 2025, Cartesian Therapeutics' Shares Outstanding (Weighted Average) is $26.0 million, which was up 0.18% from $26.0 million recorded in Q2 2025.
  • Cartesian Therapeutics' Shares Outstanding (Weighted Average)'s 5-year high stood at $26.0 million during Q3 2025, with a 5-year trough of $3.7 million in Q1 2021.
  • In the last 3 years, Cartesian Therapeutics' Shares Outstanding (Weighted Average) had a median value of $17.8 million in 2024 and averaged $15.6 million.
  • Data for Cartesian Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY skyrocketed of 391.25% (in 2024) over the last 5 years.
  • Cartesian Therapeutics' Shares Outstanding (Weighted Average) (Quarterly) stood at $3.9 million in 2021, then surged by 31.19% to $5.1 million in 2022, then climbed by 1.42% to $5.2 million in 2023, then skyrocketed by 391.25% to $25.4 million in 2024, then climbed by 6.89% to $26.0 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $26.0 million in Q3 2025, compared to $26.0 million in Q2 2025 and $25.9 million in Q1 2025.